Multiple Head and Neck Tumors Frequently Originate from a Single Preneoplastic Lesion

Tabor, Maarten P.; Brakenhoff, Ruud H.; Ruijter-Schippers, Henrique J.; Wal, Jacqueline E. van der; Snow, Gordon B.; Leemans, C. René; Braakhuis, Boudewijn J.M.

doi:10.1016/s0002-9440(10)64266-6

Cited by 184 publications

(174 citation statements)

References 25 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…topographical extension of laryngeal dysplasia are used to predict the risk for cancer and to determine the treatment strategy (Rosai et al, 1992;Zuckerberg, 2002;Johnson, 2003). Although significant efforts have been made to identify molecular markers of the clinical outcome of premalignant laryngeal lesion, still neither single nor combination of markers is accepted in clinical practice (Tabor et al, 2002). We have previously reported that both OPN and CD44v6 are highly expressed in invasive LSCC .…”

Section: Immunohistochemical Detection Of Opn and Cd44v6 In Laryngealmentioning

confidence: 99%

“…Laryngeal squamous cell carcinoma usually develops in a multistep process: normal mucosa -dysplasia (laryngeal intraepithelial neoplasia, LIN) -LSCC in situ -invasive LSCC (Rosai et al, 1992;Tabor et al, 2002;Zuckerberg, 2002;Johnson, 2003). Dysplasia is characterised by increased cell growth, cellular atypia (nuclear and nucleolar abnormalities, altered nuclear/cytoplasmatic ratio, and altered cytoplasmatic differentiation), and architectural alteration of the epithelium.…”

mentioning

confidence: 99%

“…Conventionally, the dysplastic changes are graded as mild (LIN I: dysplasia limited to the basal third of the epithelium, few mitoses), moderate (LIN II: dysplasia involving the lower two-thirds of the epithelium, marked nuclear changes, prominent nucleoli, mitoses in the parabasal, and intermediate layers), and severe (LIN III: dysplasia involving more than two-thirds of the epithelial thickness, nuclear pleomorphism and hyperchromasia, prominent nucleoli, cell crowding, and atypical mitoses). Often, severe dysplasia and in situ carcinoma are grouped in the same category (Rosai et al, 1992;Tabor et al, 2002;Zuckerberg, 2002;Johnson, 2003). Early forms of dysplasia may be reversible if the initial stimuli (like smoke and volatile irritating substances) are removed, while severe dysplasia, if left untreated, is regarded as a precancerous lesion (Rosai et al, 1992;Tabor et al, 2002;Zuckerberg, 2002;Johnson, 2003).…”

mentioning

confidence: 99%

“…Often, severe dysplasia and in situ carcinoma are grouped in the same category (Rosai et al, 1992;Tabor et al, 2002;Zuckerberg, 2002;Johnson, 2003). Early forms of dysplasia may be reversible if the initial stimuli (like smoke and volatile irritating substances) are removed, while severe dysplasia, if left untreated, is regarded as a precancerous lesion (Rosai et al, 1992;Tabor et al, 2002;Zuckerberg, 2002;Johnson, 2003). For patients with mild or moderate dysplasia, the reported rate of progression to invasive cancer is up to 11.5 and 45%, respectively.…”

mentioning

confidence: 99%

“…For patients with mild or moderate dysplasia, the reported rate of progression to invasive cancer is up to 11.5 and 45%, respectively. In severe dysplasia, higher rates of progression are commonly reported (Rosai et al, 1992;Tabor et al, 2002;Zuckerberg, 2002;Johnson, 2003). The molecular events that induce the evolution of dysplasia to carcinoma are still unknown (Cowan et al, 1992;Zuckerberg, 2002;Perez-Ordonez et al, 2006).…”

mentioning

confidence: 99%

See 4 more Smart Citations

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome

Staibano

Merolla

Testa³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

Laryngeal dysplasia is a common clinical concern. Despite major advancements, a significant number of patients with this condition progress to invasive squamous cell carcinoma. Osteopontin (OPN) is a secreted glycoprotein, whose expression is markedly elevated in several types of cancers. We explored OPN as a candidate biomarker for laryngeal dysplasia. To this aim, we examined OPN expression in 82 cases of dysplasia and in hyperplastic and normal tissue samples. OPN expression was elevated in all severe dysplasia samples, but not hyperplastic samples, with respect to matched normal mucosa. OPN expression levels correlated positively with degree of dysplasia (P ¼ 0.0094) and negatively with disease-free survival (Po0.0001). OPN expression was paralleled by cell surface reactivity for CD44v6, an OPN functional receptor. CD44v6 expression correlated negatively with disease-free survival, as well (P ¼ 0.0007). Taken as a whole, our finding identify OPN and CD44v6 as predictive markers of recurrence or aggressiveness in laryngeal intraepithelial neoplasia, and overall, point out an important signalling complex in the evolution of laryngeal dysplasia.

show abstract

Section: Immunohistochemical Detection Of Opn and Cd44v6 In Laryngealmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome

Staibano

Merolla

Testa³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

show abstract

Cancer Chemoprevention

Kim¹,

Lippman²

2007

The Cancer Handbook

View full text Add to dashboard Cite

Chemoprevention—the use of natural or synthetic chemical agents to reverse, suppress, or prevent progression to invasive cancer—is a major approach comprising laboratory and clinical research and practice for improving control of the worldwide epidemic of cancer. Chemoprevention is based on the concepts of field “cancerization” (cancer can develop in multiple foci within a field (e.g., the lung) exposed to a carcinogen (e.g., cigarette smoke)) and multistep carcinogenesis (the stepwise accumulation of genotypic and phenotypic alterations progressing through premalignant stages to cancer). Biomarkers are essential to chemoprevention research (e.g., as molecular targets for identifying new agents, markers of cancer risk for selecting trial patients, and endpoints of phase II trials). Major sites of clinical/translational chemoprevention include the lung, head and neck, breast, prostate, colorectal region, and cervix. Important clinical outcomes and advances include reducing the risks of breast cancer with tamoxifen and raloxifene, prostate cancer with finasteride, cervical intraepithelial neoplasia with HPV vaccine, and familial adenomatous polyposis with celecoxib. Major current and/or future directions of chemoprevention include molecular‐targeted research, novel imaging and other technologies aimed at developing personalized chemoprevention, and convergent development of molecular‐targeted drugs for preventing and treating precancer and cancer.

show abstract

Detection and clinical outcome of urinary bladder cancer with 5‐aminolevulinic acid‐induced fluorescence cystoscopy

Stenzl¹,

Penkoff²,

Dajc-Sommerer³

et al. 2010

Cancer

105

View full text Add to dashboard Cite

BACKGROUND:The medical community lacks results from prospective controlled multicenter studies of the diagnostic efficacy of 5-aminolevulinic acid (5-ALA) cystoscopy on tumor recurrence in patients with superficial bladder tumors. METHODS: A prospective randomized, double-blind, placebo-controlled study was conducted in 370 patients with nonmuscle-invasive urinary bladder carcinoma who received either 5-ALA (n ¼ 187) or a placebo (n ¼ 183) intravesically before cystoscopy. Each group underwent cystoscopy under visible white light and under fluorescent light followed by transurethral tumor resection. The primary study objective was to evaluate the 12-month recurrence-free survival. RESULTS: Slightly more patients with tumors were detected by using 5-ALA than by using the placebo (88.5% vs 84.7%). The mean numbers of tumor specimens per patient were 1.8 (5-ALA) and 1.6 (placebo). Intrapatient comparison of fluorescent light versus white light cystoscopy in patients randomized to receive 5-ALA showed a higher tumor detection rate with fluorescent light than with white light cystoscopy. In patients receiving 5-ALA cystoscopy, the percentage of lesions that would not have been detected in these patients by white light cystoscopy ranged between 10.9% (pT1) and 55.9% (atypia). Progression-free survival was 89.4% (5-ALA) and 89.0% (placebo) (P ¼ .9101), and recurrence-free survival 12 months after tumor resection was 64.0% (5-ALA) and 72.8% (placebo) (P ¼ .2216). CONCLUSIONS: In comparison to the placebo, 5-ALA cystoscopy did not increase the rates of recurrence-free or progression-free survival 12 months after tumor resection. Although more tumors per patient were detected in the 5-ALA group, the higher detection rate did not translate into differences in long-term outcome.

show abstract

Multiple Head and Neck Tumors Frequently Originate from a Single Preneoplastic Lesion

Cited by 184 publications

References 25 publications

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome

Cancer Chemoprevention

Detection and clinical outcome of urinary bladder cancer with 5‐aminolevulinic acid‐induced fluorescence cystoscopy

Contact Info

Product

Resources

About